From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.
You may also be interested in...
While a cloud hangs over the future of its CD19-targeting allogeneic candidate, points to preclinical potential of superior efficacy for ALLO-715.
The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.
Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.